Genetically conditioned interaction among micro RNA ‐155, alpha‐klotho, and intra‐renal RAS in male rats: Link to CKD progression
Physiological Reports · 2024
DOI: 10.14814/phy2.16172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2024. Verfasst von L M Harrison-Bernard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Glucuronidase, Klotho Proteins, MicroRNAs, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, DOD | US Army | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP), HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Abstract (Originalsprache)
Incident chronic kidney disease (CKD) varies in populations with hypertension of similar severity. Proteinuria promotes CKD progression in part due to activation of plasminogen to plasmin in the podocytes, resulting in oxidative stress‐mediated injury. Additional mechanisms include deficiency of renal alpha‐klotho, that inhibits Wnt/beta‐catenin, an up regulator of intra‐renal renin angiotensin system (RAS) genes. Alpha‐klotho deficiency therefore results in upregulation of the intra‐renal RAS via Wnt/beta‐catenin. In hypertensive, Dahl salt sensitive (DS) and spontaneously hypertensive rats (SHR), we investigated renal and vascular injury, miR‐155, AT1R, alpha‐klotho, and TNF‐α. Hypertensive high salt DS (DS‐HS), but not SHR developed proteinuria, plasminuria, and glomerulosclerosis. Compared to DS low salt (DS‐LS), in hypertensive DS‐HS alpha‐klotho decreased 5‐fold in serum and 2.6‐fold in kidney, whereas serum mir‐155 decreased 3.3‐fold and AT1R increased 52% in kidney and 77% in aorta. AT1R, alpha‐klotho, and miR‐155 remained unchanged in prehypertensive and hypertensive SHR. TNF‐α increased by 3‐fold in serum and urine of DS‐HS rats. These studies unveiled in salt sensitive DS‐HS, but not in SHR, a genetically conditioned dysfunction of the intermolecular network integrated by alpha‐klotho, RAS, miR‐155, and TNF‐α that is at the helm of their end‐organ susceptibility while plasminuria may participate as a second hit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
- Katz Family Division of Nephrology, University of Miami Miller School of Medicine, Miami, Florida, USA.
- South Florida Veterans Administration Foundation, Miami, Florida, USA.
- Renal Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
ORCID-Profile: E A Jaimes
Förderung
- NCI NIH HHS
- DOD | US Army | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Cancer Institute
- Congressionally Directed Medical Research Programs
Zitieren
APA
Harrison-Bernard, L. M., Raij, L., Tian, R. X., & Jaimes, E. A. (2024). Genetically conditioned interaction among micro RNA ‐155, alpha‐klotho, and intra‐renal RAS in male rats: Link to CKD progression. Physiological Reports. https://doi.org/10.14814/phy2.16172
Vancouver
Harrison-Bernard LM, Raij L, Tian RX, Jaimes EA. Genetically conditioned interaction among micro RNA ‐155, alpha‐klotho, and intra‐renal RAS in male rats: Link to CKD progression. Physiological Reports. 2024. doi:10.14814/phy2.16172
BibTeX
@article{HarrisonBernard2024,
author = {Harrison-Bernard, L M and Raij, L and Tian, R X and Jaimes, E A},
title = {Genetically conditioned interaction among micro RNA ‐155, alpha‐klotho, and intra‐renal RAS in male rats: Link to CKD progression},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.16172}
}
EUVIMED